Reuters notes that of the 10,000 Americans the companies hoped to treat by the end of March, Eisai announced that only a couple thousand had begun treatment as of January. Biogen and Eisai intend ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug has been recommended by the European Medicines Agency’s human medicines ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

Ivana Rubino works at Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States. Bruce Albala works at Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease ...

"Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today a positive opinion has been received from the ...